News - TOSP

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

The Oxford Science Park welcomes Cowley Branch Line announcement

23 Oct 2025

The Oxford Science Park (TOSP) has welcomed today’s announcement by the Chancellor of the Exchequer, Rachel Reeves, confirming government funding of £120m for the reopening of the Cowley Branch Line to passengers. The decision marks a significant milestone in improving transport links for Oxford’s growing innovation district. The project will reconnect Cowley and Littlemore with Oxford city centre and beyond through two new stations with one... Read more

The Oxford Science Park announces strategic sale to the Ellison Institute of Technology

14 Oct 2025

The Oxford Science Park (TOSP), one of Europe’s leading destinations for science and technology companies, today announced the sale of part of its estate to the Ellison Institute of Technology (EIT). The transaction is a strategic step in a partnership between TOSP and EIT to support discovery, innovation and entrepreneurship in Oxford, and make it a truly global hub for scientific research and development. The sale enables EIT to expand... Read more

Ambassador visits The Oxford Science Park to boost European trade opportunities

09 Oct 2025

The UK’s Ambassador to the EU, Lindsay Appleby, visited The Oxford Science Park this week as part of a two-day tour of Oxfordshire aimed at helping local businesses seize new growth opportunities within European markets. The visit formed part of the Government’s nationwide ‘domestic roadshow’, which is sending Ambassadors and High Commissioners to communities across the UK to strengthen links with businesses and support their expansion into... Read more

Theolytics appoints new Chief Medical Officer

08 Oct 2025

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has announced the appointment of Matilde Saggese, MD, as Chief Medical Officer (CMO). Dr Saggese will lead clinical development and regulatory activities for Theolytics, including for its lead asset THEO-260, which is being investigated in UK and US trials evaluating two different routes of administration (IV and IP, respectively) in... Read more

Sitryx receives FDA clearance to progress trials of oral treatment of atopic dermatitis

03 Oct 2025

Sitryx Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for SYX-5219, to support the initiation of a Phase 1b trial in adults with moderate to severe atopic dermatitis in the United States. The Company expects to... Read more